Zacks Investment Research on MSN2h
Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report?
A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 7.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio?
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...
MaxCyte price target lowered to $6 from $8 at BTIG
BTIG analyst Mark Massaro lowered the firm’s price target on MaxCyte (MXCT) to $6 from $8 and keeps a Buy rating on the shares after its Q4 ...
Rep. Jefferson Shreve Purchases Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had ...
Investing Snacks15h
Vertex’s Next Decade: Bigger, Bolder, and Beyond CF
Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...
Tracking Renaissance Technologies 13F Portfolio - Q4 2024 Update
Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...
11 Best Pharma Stocks to Buy According to Hedge Funds
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.